Bruce Kava, MD
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.9%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Merit Medical Systems Inc at 34.5% of the total. Reporting peaked in 2019 at $25,417 and has fallen 57.9% since, to $10,705 in 2025. Among urology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 275 payments — averaging $160.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merit Medical Systems Inc$15K
- Endo USA, Inc.$8K
- Coloplast$5K
- Endo Pharmaceuticals Inc.$5K
- Boehringer Ingelheim$5K
- Boston Scientific$2K
- plus $5K from 19 others
Across 3 payments — averaging $2135.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Endo USA, Inc.$6K
What the payments were for
- Consulting fees$24,26555%
- Speaking & faculty fees$4,57810%
- Travel & lodging$3,9929%
- Food & beverage$11,16025%
- Education$1800%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merit Medical Systems Inc | 7 | $15,257 |
| Endo USA, Inc. | 20 | $7,730 |
| Coloplast | 55 | $5,017 |
| Endo Pharmaceuticals Inc. | 38 | $4,720 |
| Boehringer Ingelheim | 1 | $4,578 |
| Boston Scientific | 42 | $2,064 |
| Procept Biorobotics Corporation | 18 | $1,963 |
| AbbVie(2 entities) | 15 | $416 |
| Johnson & Johnson | 14 | $331 |
| Teleflex LLC | 5 | $319 |
| Astellas Pharma US Inc | 11 | $222 |
| Sumitomo Pharma America, Inc. | 11 | $207 |
| Urovant Sciences Inc | 6 | $204 |
| Axonics, Inc. | 3 | $186 |
| Neotract Inc. | 1 | $132 |
| Pfizer | 7 | $118 |
| Antares Pharma, Inc. | 3 | $116 |
| Osprey Medical Inc | 3 | $116 |
| Ambu Inc. | 5 | $115 |
| Verity Pharmaceuticals Inc. | 4 | $95 |
| Integra Lifesciences Corporation | 1 | $92 |
| Merck | 1 | $75 |
| Bayer | 1 | $50 |
| Ferring Pharmaceuticals Inc. | 2 | $33 |
| Urogen Pharma, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XIAFLEX$11,222
- Embosphere Microspheres$10,600
- APTIVUS$4,578
- TITAN$3,812
- AquaBeam Robotic System$1,719
- REZUM$677
- UroLift$270
- AMS 700$160
- Axonics$141
- GENERAL VASCULAR INTERVENTION$139
- Lupron Depot$125
- GREENLIGHT$124
- GEMTESA$123
- AMS 700 CXR RTE KIT$105
How this compares
$44,174 in reported general payments places this provider in the 90th percentile of 935 urology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiaflexCollagenase Clostridium Hist. | 24 | $307,436 |
| MyrbetriqMirabegron | 183 | $121,594 |
| GemtesaVibegron | 83 | $68,006 |
| Solifenacin Succinate | 165 | $8,681 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 370 | $7,759 |
| Testosterone | 69 | $5,731 |
| Tamsulosin Hcl | 357 | $5,692 |
| Testosterone Cypionate | 160 | $4,756 |
| Silodosin | 29 | $4,497 |
| Methenamine Hippurate | 47 | $3,195 |
| Finasteride | 126 | $1,778 |
| Tadalafil | 19 | $1,322 |
| Tolterodine Tartrate ErTolterodine Tartrate | 11 | $1,251 |
| Oxybutynin Chloride ErOxybutynin Chloride | 38 | $951 |
| Cabergoline | 17 | $859 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Endo Pharmaceuticals Inc.Xiaflex | $4,720 | $307,43624 claims |
| Astellas Pharma US IncMyrbetriq | $222 | $121,594183 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $207 | $68,00683 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 935 urology providers in Florida.
Other urology in Miami
- Mark Anthony GonzalgoMiami$1M
- Daniel MartinezMiami$133K
- Emad IbrahimMiami$85K
- Sanoj PunnenMiami$48K
- Ahmed EldefrawyMiami$47K
- Paul PeritoCoral Gables$3.6M
- Scott SellingerTallahassee$2.3M
- Edward GheilerHialeah$655K
- Rolando RiveraNaples$437K
- Matthew ErcolaniVenice$416K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.